相似文献
1
Review of frovatriptan in the treatment of migraine.
Neuropsychiatr Dis Treat. 2008 Feb;4(1):49-54. doi: 10.2147/ndt.s1871.
2
A review of the use of frovatriptan in the treatment of menstrually related migraine.
Ther Adv Neurol Disord. 2013 Mar;6(2):55-67. doi: 10.1177/1756285612470191.
3
A review of frovatriptan for the treatment of menstrual migraine.
Int J Womens Health. 2014 May 21;6:523-35. doi: 10.2147/IJWH.S63444. eCollection 2014.
4
Pharmacokinetic evaluation of frovatriptan.
Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1449-58. doi: 10.1517/17425255.2011.622265. Epub 2011 Sep 20.
5
Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine.
Drug Des Devel Ther. 2016 Oct 3;10:3225-3236. doi: 10.2147/DDDT.S105932. eCollection 2016.
6
Managing migraine by patient profile: role of frovatriptan.
Patient Prefer Adherence. 2016 Apr 5;10:501-10. doi: 10.2147/PPA.S85795. eCollection 2016.
7
Frovatriptan review.
Expert Opin Pharmacother. 2007 Dec;8(17):3029-33. doi: 10.1517/14656566.8.17.3029.
8
Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies.
Gend Med. 2010 Apr;7(2):88-108. doi: 10.1016/j.genm.2010.04.006.
9
Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination.
Curr Med Res Opin. 2009 Nov;25(11):2711-21. doi: 10.1185/03007990903285449.
10
Efficacy of frovatriptan as compared to other triptans in migraine with aura.
J Headache Pain. 2015;16:514. doi: 10.1186/s10194-015-0514-8. Epub 2015 Apr 1.
引用本文的文献
1
Visible-Light-Mediated Rose Bengal- or [Ru(bpy)]-Catalyzed Radical [4 + 2] Cycloaddition: An Efficient Route to Tetrahydrocarbazoles.
ACS Omega. 2025 Mar 7;10(10):10713-10723. doi: 10.1021/acsomega.5c00416. eCollection 2025 Mar 18.
2
Selective C-H Activation of Unprotected Allylamines by Control of Catalyst Speciation.
Chem Catal. 2023 Nov 16;3(11). doi: 10.1016/j.checat.2023.100809. Epub 2023 Nov 8.
3
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure.
J Headache Pain. 2022 Nov 22;23(1):148. doi: 10.1186/s10194-022-01519-4.
4
Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
Headache. 2019 Apr;59(4):509-517. doi: 10.1111/head.13482. Epub 2019 Jan 30.
5
Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.
J Neurophysiol. 2016 Jan 1;115(1):208-17. doi: 10.1152/jn.00632.2015. Epub 2015 Oct 21.
6
Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group study.
Neurol Sci. 2015 May;36 Suppl 1:161-7. doi: 10.1007/s10072-015-2165-6.
7
Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.
Drug Des Devel Ther. 2014 Jul 21;8:983-92. doi: 10.2147/DDDT.S61295. eCollection 2014.
8
Gender and triptan efficacy: a pooled analysis of three double-blind, randomized, crossover, multicenter, Italian studies comparing frovatriptan vs. other triptans.
Neurol Sci. 2014 May;35 Suppl 1(Suppl 1):99-105. doi: 10.1007/s10072-014-1750-4.
9
Symptomatic or prophylactic treatment of weekend migraine: an open-label, nonrandomized, comparison study of frovatriptan versus naproxen sodium versus no therapy.
Neuropsychiatr Dis Treat. 2013;9:81-5. doi: 10.2147/NDT.S39373. Epub 2013 Jan 16.
10
Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan.
J Headache Pain. 2011 Dec;12(6):609-15. doi: 10.1007/s10194-011-0366-9. Epub 2011 Aug 13.
本文引用的文献
1
Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Headache. 2007 Jul-Aug;47(7):1037-49. doi: 10.1111/j.1526-4610.2007.00855.x.
2
Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.
Headache. 2007 Jun;47(6):886-94. doi: 10.1111/j.1526-4610.2007.00809.x.
3
Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.
Cephalalgia. 2007 May;27(5):414-21. doi: 10.1111/j.1468-2982.2007.01313.x.
4
The discovery of a new drug class for the acute treatment of migraine.
Headache. 2007 Apr;47 Suppl 1:S10-9. doi: 10.1111/j.1526-4610.2007.00672.x.
5
Migraine prevalence, disease burden, and the need for preventive therapy.
Neurology. 2007 Jan 30;68(5):343-9. doi: 10.1212/01.wnl.0000252808.97649.21.
6
Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
CNS Drugs. 2006;20(12):1019-26. doi: 10.2165/00023210-200620120-00005.
7
Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine.
Neurol Sci. 2006 May;27 Suppl 2:S193-7. doi: 10.1007/s10072-006-0600-4.
8
The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF).
J Headache Pain. 2005 Dec;6(6):429-40. doi: 10.1007/s10194-005-0252-4. Epub 2005 Dec 15.
9
A positron emission tomographic study in spontaneous migraine.
Arch Neurol. 2005 Aug;62(8):1270-5. doi: 10.1001/archneur.62.8.1270.
10
Migraine pathophysiology.
Headache. 2005 Apr;45 Suppl 1:S14-24. doi: 10.1111/j.1526-4610.2005.4501003.x.
Zotero 插件